Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
暂无分享,去创建一个
Ariel Hammerman | John Hornberger | Julie Doberne | J. Hornberger | S. Klang | A. Hammerman | N. Liebermann | N. Efrat | Julie W. Doberne | Nicky Liebermann | Shmuel H Klang | Noa Efrat
[1] P. Tartter,et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? , 2008, American journal of surgery.
[2] J. Hornberger,et al. Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancer , 2007, Cancer.
[3] B Fisher,et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.
[4] A. Cohn,et al. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. , 2007, Journal of oncology practice.
[5] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[6] Giovanni Parmigiani,et al. Impact of gene expression profiling tests on breast cancer outcomes. , 2007, Evidence report/technology assessment.
[7] R. Feachem. Commission on Macroeconomics and Health. , 2002, Bulletin of the World Health Organization.
[8] C. Zimmermann,et al. Framing of outcome and probability of recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios , 2000, Breast Cancer Research and Treatment.
[9] Donald L Weaver,et al. Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975–1999 , 2002, Cancer.
[10] L. Ries,et al. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. , 2006 .
[11] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[12] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[13] J. Barendregt,et al. Global burden of disease , 1997, The Lancet.
[14] V. Brennan,et al. PCN77 A SYSTEMATIC REVIEW OF BREAST CANCER UTILITY WEIGHTS , 2008 .
[15] C. Balch,et al. AJCC Cancer Staging Manual. 6th ed , 2002 .
[16] S. Klang,et al. A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients , 2007 .
[17] P. Ravdin,et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Hiroshi Ishiguro,et al. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan , 2008, Breast Cancer Research and Treatment.
[19] York Springer,et al. Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .
[20] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Gary H Lyman,et al. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.
[22] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. T. Sawyer,et al. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Simes,et al. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? , 2001, Journal of the National Cancer Institute. Monographs.
[26] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[27] M. Roberts,et al. Incorporating Quality of Evidence into Decision Analytic Modeling , 2007, Annals of Internal Medicine.